Shares of Kailera Therapeutics leapt 63% on debut after an upsized initial public offering that raised $625 million. The surge followed the company’s decision to lift its IPO price range, signaling strong investor appetite for therapies aimed at chronic weight management. The move places Kailera among the most successful biotech debuts of the year.

The flotation, priced between $20 and $22 per share, drew more than 1.4 million investors, reflecting growing confidence in obesity treatments as a lucrative segment. Analysts note that the capital influx will fund late‑stage trials and expand the company’s pipeline, potentially positioning Kailera as a key player in a market projected to reach multi‑billion‑dollar valuations.

The IPO’s success underscores the market’s willingness to back niche therapeutic areas despite regulatory hurdles. With the new capital, Kailera aims to accelerate product development and broaden its clinical portfolio, which could reshape investor focus toward weight‑management biologics. As a result, the company’s valuation jumps sharply, offering a rare high‑yield opportunity in a crowded biotech landscape.

Market participants will monitor Kailera’s next clinical milestones closely, as progress could unlock further funding rounds and attract partnership talks with larger pharma houses. The IPO also signals that investors are willing to pay premium valuations for companies that promise breakthroughs in a disease area with significant unmet need.